Mizuho on Sarepta Therapeutics (SRPT): 'Lowering 3Q25 Elevidys Sales Below Consensus'
Tweet Send to a Friend
Mizuho analyst Uy Ear reiterated a Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
